Pharmaceutical

Global PD-1 and PD-L1 Inhibitors Market 2019-2023 | Evolving Opportunities with AstraZeneca and Merck | Technavio

Biotechnology, Pharmaceutical, Health, Phosphodiesterase inhibitors, Branches of biology, Molecular biology, Phosphodiesterase, PD-1 and PD-L1 inhibitors, PD-L1, Biology
Friday, January 17, 2020 - 11:00pm

View the full release here: https://www.businesswire.com/news/home/20200117005292/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200117005292/en/
    Technavio has announced its latest market research report titled global PD-1 and PD-L1 inhibitors market 2019-2023.
  • The proven efficiency of PD-1 and PD-L1 inhibitors and strong pipeline are among factors anticipated to boost the growth of the market.
  • Request a free sample report
    Related Reports on Health Care include:
    MEK Inhibitors Market Global MEK Inhibitors Market by product (MEKINIST, COTELLIC, and MEKTOVI) and geography (Asia, Europe, North America, and ROW).
  • Phosphodiesterase (PDE) inhibitors Market Global Phosphodiesterase (PDE) inhibitors Market by application (oral, topical, and other RoA), and geography (Asia, Europe, North America, and ROW).

Northern California Rite Aid Workers Vote to Reject the Company’s Offer by 91%

Public policy, Government, Pharmaceutical, General Health, Health, Specialty, Convenience store, Labor, Retail, Rite Aid, Shift work, Human activities, Work, Health
Friday, January 17, 2020 - 7:48pm

Health care benefits were promised to retirees throughout their years working for Rite Aid.

Key Points: 
  • Health care benefits were promised to retirees throughout their years working for Rite Aid.
  • The companys offer includes a wage increase for workers but also shifts more medical costs to the workers, negating Rite Aid's proposed increase.
  • Customers also sounded off in support of Rite Aid workers.
  • I will never shop at Rite Aid again if you hurt your workers."

Clinical Trials Research Seeking Participants for Reducing Symptoms of Menopause in Women

Science, Women, Research, Pharmaceutical, Health, Hospitals, Consumer, Clinical trials, Health, Articles, Clinical research, Pharmaceutical industry, Design of experiments, Clinical pharmacology, Clinical trial, Hot flash, Institutional review board, Contract research organization
Friday, January 17, 2020 - 7:37pm

More than two-thirds of North American women who are heading into menopause have hot flashes.

Key Points: 
  • More than two-thirds of North American women who are heading into menopause have hot flashes.
  • Clinical Trials Research (CTR), located in Lincoln and Sacramento, is seeking participants for a study researching investigational medications that could help to reduce symptoms associated with menopause.
  • Clinical Trials Research is a clinical research site with two locations providing coverage to the greater Sacramento area in northern California.
  • Clinical Trials Research collaborates with well-known Pharmaceuticals (Sponsors), Contract Research Organizations (CROs) and Institutional Review Boards (IRBs) for the purpose of enhancing the lives of millions through the pursuit of medical innovation and research.

Global Epidermolysis Bullosa Therapeutics Market 2019-2023 | Evolving Opportunities With Fresenius and Novartis | Technavio

Pharmaceutical, Health, Other Health, Genodermatoses, Rare diseases, Fresenius, Societates Europaeae, Health, Epidermolysis bullosa, Economy of Germany, Companies
Friday, January 17, 2020 - 6:30pm

View the full release here: https://www.businesswire.com/news/home/20200117005270/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200117005270/en/
    Technavio has announced its latest market research report titled global epidermolysis bullosa therapeutics market 2019-2023.
  • The current range of therapeutics for the treatment of epidermolysis bullosa available in the market have some side effects.
  • Similarly, the Epidermolysis Bullosa Medical Research Foundation (EBMRF) is also funding innovative research to develop a cure for epidermolysis bullosa.
  • Fresenius is headquartered in Germany and offers products through the following business units: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed.

Global Animal Medicine Market Opportunities And Strategies During the Forecast Period, 2019-2023 - ResearchAndMarkets.com

Pharmaceutical, Health, Veterinary, Image segmentation
Friday, January 17, 2020 - 5:28pm

Global Animal Medicine Market, 2019-2023, Growth And Market Share Comparison, By Region

Key Points: 
  • Global Animal Medicine Market, 2019-2023, Growth And Market Share Comparison, By Region
    15.1.
  • Global Animal Medicine Market, Segmentation By Type Of Medicine, 2015 - 2023, Value ($ Billion)
    15.2.
  • Global Animal Medicine Market, Segmentation By Type Of Animal, 2015 - 2023, Value ($ Billion)
    15.3.
  • Per Capita Average Animal Medicine Market Expenditure, Global

Veterinary Pharmaceuticals Global Market Opportunities And Strategies To 2030 - ResearchAndMarkets.com

Pharmaceutical, Health, Veterinary, Pharmaceutical industry in India, Pharmaceutical industry in China, Health, Articles
Friday, January 17, 2020 - 5:14pm

The "Veterinary Pharmaceuticals Global Market Opportunities And Strategies To 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Veterinary Pharmaceuticals Global Market Opportunities And Strategies To 2030" report has been added to ResearchAndMarkets.com's offering.
  • Veterinary Pharmaceuticals Global Market Opportunities And Strategies To 2030 from the author provides the strategists, marketers and senior management with the critical information they need to assess the global veterinary pharmaceuticals market.
  • Where is the largest and fastest-growing market for the veterinary pharmaceuticals market?
  • The global veterinary pharmaceutical market report to 2030 from the author answers all these questions and many more.

First Opioid Treatment Medication Unit in Ohio Opens Monday by Pinnacle Treatment Centers

Health, Consumer, Hospitals, Women, General Health, MEN, Pharmaceutical, Psychoactive drugs, RTT, Drugs, Analgesics, Morphinans, Euphoriants, Opioid epidemic in the United States, Sackler family, Heroin
Friday, January 17, 2020 - 5:07pm

Pinnacle Treatment Centers , a leader in providing accessible treatment for adult men and women struggling with substance use disorder, will open Georgetown Treatment Services, Ohios first medication unit, on Monday.

Key Points: 
  • Pinnacle Treatment Centers , a leader in providing accessible treatment for adult men and women struggling with substance use disorder, will open Georgetown Treatment Services, Ohios first medication unit, on Monday.
  • Geographically separated from its home opioid treatment program (OTP), a medication unit must be located within 45-90 miles of its main clinic, which provides the full range of medication-assisted treatment (MAT) services including individual and group counseling.
  • Joe Pritchard, CEO of Pinnacle Treatment Centers headquartered in New Jersey, stated, Ohios need for a broader range of opioid treatment is clear, particularly in rural counties like Brown.
  • Pinnacle Treatment Centers is a recognized leader in comprehensive substance use treatment services.

ERS Genomics Provides Comment on EPO Technical Board of Appeal Decision Upholding the Revocation of Broad Institute CRISPR Patent

Biotechnology, Health, Professional services, Pharmaceutical, Legal, Monopoly, Patent, European Patent Organisation, Patent law
Friday, January 17, 2020 - 4:50pm

EP2771468 is viewed as the Broad Institutes foundational CRISPR-Cas9 patent in Europe.

Key Points: 
  • EP2771468 is viewed as the Broad Institutes foundational CRISPR-Cas9 patent in Europe.
  • The Broad Institute appealed the Opposition Divisions decision, which the Board affirmed yesterday.
  • Thus, all claims of the Broad Institutes patent remain fully revoked with no option left to overturn this decision.
  • The Broad Institute obtained nine other patents that all suffer from the very same defect that resulted in the revocation of this first patent.

UnitedHealthcare and Optum Take Action to Support People Affected by Severe Weather in Mississippi

Mental health, Health, Professional services, Pharmaceutical, Insurance, Optum, UnitedHealth Group, Companies, Articles, Mental health, UNH, Psychological stress, Health
Friday, January 17, 2020 - 3:31pm

UnitedHealthcare and Optum, the health benefits and services companies of UnitedHealth Group (NYSE: UNH), are taking action to help people who may be affected by the severe weather in Mississippi.

Key Points: 
  • UnitedHealthcare and Optum, the health benefits and services companies of UnitedHealth Group (NYSE: UNH), are taking action to help people who may be affected by the severe weather in Mississippi.
  • The app is available now for download at no additional charge for Android and Apple devices to people enrolled in UnitedHealthcare health benefit plans.
  • Free Help Line: Optum, a leading health and behavioral health services company, is offering a free emotional-support help line.
  • Specially trained Optum mental health specialists help people manage their stress and anxiety so they can continue to address their everyday needs.

RAC Alpha Serine Threonine Protein Kinase - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Health, Pharmaceutical, Enzymes, Protein kinases, AKT1, Oncogenes, Serine/threonine-specific protein kinase, Protein kinase B, Book:Bc3sigtrann, AKT2
Friday, January 17, 2020 - 2:20pm

The "RAC Alpha Serine Threonine Protein Kinase - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "RAC Alpha Serine Threonine Protein Kinase - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2019'; RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) pipeline Target constitutes close to 13 molecules.
  • RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - RAC-alpha serine/threonine-protein kinase is an enzyme encoded by the AKT1 gene.
  • The report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2019' outlays comprehensive information on the RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.